Lilly, Nvidia back biotech firm Superluminal

Biotech start-up Superluminal Medicines will develop six new small molecules with the help of $120 million in new funding. Superluminal is using generative artificial intelligence to help design small-molecule medicines that target G protein–coupled receptors, as well as ion channels and transporters. The firm has not disclosed any specific disease areas. Superluminal is based in Eli Lilly & Company’s incubator space in Boston. Lilly participated in Superluminal’s series A financing round, as did NVentures, the venture capital arm of the tech company Nvidia.